Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 16;7(1):1494482. doi: 10.1080/20013078.2018.1494482

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of The International Society for Extracellular Vesicles.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Immuno-capture specificity.

A comparison of the efficiency of magnetic beads coated with various antibodies for isolating MVs with plasmin-generation capacity. MV-PGC was measured after IMS either on the spiked PFP or the plasma remaining after the first round of IMS. The IMS-CD15 was used as a reference (100%). Ctl = control. IMS was performed using magnetic beads coated with an irrelevant (anti-DNP) antibody. B. Impact of the coating of CD15-beads on MV-PGC. MV-PGC using primary or secondary bound CD15-beads was compared. Beads coated with an irrelevant antibody were used as control (n = 4). NS: no significant. C. Flow cytometry analysis of CD15 expression on purified PMN-MVs (CD66b+/AnnV+ events) or Mono-MVs (CD11b+/AnnV+ events) spiked in MVFP. D. Residual Leu-MVs (AnnV+/CD15+) and PMVs (AnnV+/CD41+) were detected by flow cytometry after sequential IMS on human PFP enriched with purified PMN-MVs (with the Leu-MV:PMV ratio being close to 1, i.e., 50%:50%): 1. IMS-IgG; 2. IMS-CD15; and 3. IMS-CD41.